Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
Status:
RECRUITING
Trial end date:
2025-07-04
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, vehicle-controlled phase III study to evaluate the efficacy, safety, and PK profile of roflumilast cream 0.3% in Chinese subjects 6 years of age with plaque psoriasis.